Frexalimab not checked

Sanofi · SAR441344

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
10 active
12 in total · 10 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Pharmaceutical form:Concentrate for solution for infusion-Route of administration:IV infusion”In the company’s words, NCT07325292 on ClinicalTrials.gov
Tested for
Multiple Sclerosis (5 trials), Kidney Transplant Rejection, Systemic Lupus Erythematosus, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
Main trialPhase 3
“The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration depending on the recruitment rate, the event rate, the…”In the company’s words, NCT06141473 on ClinicalTrials.gov
Other names
SAR441344

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Coming up7

Changes1

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 6 May 2027 Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Phase 3Recruiting 15 Jul 2027 Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Phase 3Active, not recruiting 24 Mar 2028 Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Phase 3Not yet recruiting 16 May 2031 A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis
Phase 2/3Recruiting 15 Aug 2029 A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Phase 2Active, not recruiting 21 Sep 2022 Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Phase 2Active, not recruiting 4 Sep 2026 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Phase 2Recruiting 23 Dec 2026 A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Phase 2Active, not recruiting 28 Apr 2027 Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Phase 2Completed 8 Nov 2023 Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Phase 1Completed 10 Apr 2020 Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects
Phase 3Authorised not given Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Frexalimab

Following is part of Solo: you see every change to Frexalimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in